{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:05:12Z","timestamp":1776071112437,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"European Union's Horizon Europe research and innovation programme","doi-asserted-by":"publisher","award":["101095593"],"award-info":[{"award-number":["101095593"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/20523211.2026.2651404","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:22:35Z","timestamp":1776068555000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-716X","authenticated-orcid":false,"given":"Vittoria","family":"Ardito","sequence":"first","affiliation":[{"name":"SDA Bocconi School of Management","place":["Milan, Italy"]},{"name":"University of Hamburg","place":["Hamburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lasse","family":"Falk","sequence":"additional","affiliation":[{"name":"University of Hamburg","place":["Hamburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Gasol Boncompte","sequence":"additional","affiliation":[{"name":"Servei Catal\u00e0 de la Salut","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-6048","authenticated-orcid":false,"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[{"name":"Universitat Autonoma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-3017","authenticated-orcid":false,"given":"James","family":"Robinson","sequence":"additional","affiliation":[{"name":"SDA Bocconi School of Management","place":["Milan, Italy"]},{"name":"University of California","place":["Berkeley, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-2161","authenticated-orcid":false,"given":"Jonas","family":"Schrey\u00f6gg","sequence":"additional","affiliation":[{"name":"University of Hamburg","place":["Hamburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-0508","authenticated-orcid":false,"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[{"name":"SDA Bocconi School of Management","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"AIFA. (2025). AIFA: si accorciano i tempi delle procedure di ammissione alla rimborsabilit\u00e0 dei farmaci. AIFA. https:\/\/www.aifa.gov.it\/-\/si-accorciano-i-tempi-delle-procedure-per-la-rimborsabilita."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01435-2"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.08.008"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2504699"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232300048X"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13308"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.3961"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-021-00712-x"},{"key":"e_1_3_6_10_1","unstructured":"EFPIA. (2023). EFPIA patients W.A.I.T. indicator 2022 survey. https:\/\/www.efpia.eu\/media\/s4qf1eqo\/efpia_patient_wait_indicator_final_report.pdf."},{"key":"e_1_3_6_11_1","unstructured":"EMA. (2016a). Conditional marketing authorisation. Report on ten years of experience at the European Medicines Agency. EMA. https:\/\/www.ema.europa.eu\/en\/documents\/report\/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf."},{"key":"e_1_3_6_12_1","unstructured":"EMA. (2016b). Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004. EMA. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf."},{"key":"e_1_3_6_13_1","unstructured":"EMA. (2024). Annual reports and work programmes. https:\/\/www.ema.europa.eu\/en\/about-us\/annual-reports-work-programmes#2006-9675."},{"key":"e_1_3_6_14_1","unstructured":"EMA. (2025a). Accelerated assessment. EMA. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/accelerated-assessment."},{"key":"e_1_3_6_15_1","unstructured":"EMA. (2025b). Conditional marketing authorization. EMA. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation."},{"key":"e_1_3_6_16_1","unstructured":"EMA. (2025c). PRIME: priority medicines. EMA. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines."},{"key":"e_1_3_6_17_1","unstructured":"European Commission. (2006). European Commission 2006. Commission Regulation (EC) No 507\/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 of the European Parliament and of the Council. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32006R0507."},{"key":"e_1_3_6_18_1","unstructured":"European Commission\/EXPH. (2018). Opinion on innovative payment models for high-cost innovative-medicines. Publications Office. https:\/\/data.europa.eu\/doi\/10.2875835008."},{"key":"e_1_3_6_19_1","unstructured":"European Parliament and Council. (2004). European Parliament and Council 2004. Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32004R0726."},{"key":"#cr-split#-e_1_3_6_20_1.1","unstructured":"European Parliament and Council. (2021). Regulation"},{"key":"#cr-split#-e_1_3_6_20_1.2","unstructured":"(EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011\/24\/EU. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32021R2282."},{"key":"e_1_3_6_21_1","unstructured":"FDA. (2023). Benefit-risk assessment for new drug and biological products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/benefit-risk-assessment-new-drug-and-biological-products."},{"key":"e_1_3_6_22_1","unstructured":"FDA. (2025). Accelerated approval program. FDA. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12498"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.00119"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01201-z"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2306872"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1959"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307070651"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-025-00771-5"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3554"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123193"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.04.010"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1383"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2416240"},{"key":"e_1_3_6_35_1","unstructured":"MHRA. (2025). Innovative licensing and access program (ILAP). MHRA. https:\/\/www.gov.uk\/guidance\/innovative-licensing-and-access-pathway."},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01248-9"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.008"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9415"},{"key":"e_1_3_6_39_1","unstructured":"Newton M. Stoddart K. Travaglio M. & Troein P. (2024). EFPIA patients W.A.I.T. indicator 2023 survey. EFPIA. https:\/\/efpia.eu\/media\/vtapbere\/efpia-patient-wait-indicator-2024.pdf."},{"key":"e_1_3_6_40_1","unstructured":"NIPH\/WHO. (2025). Norwegian Institute of Public Health \u2013 World Health Organization Collaborating Centre for Drug Statistics and Methodology. Anatomical therapeutic chemical classification. https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462318000363"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20220112.876687"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00196"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12020008"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002873"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-018-0209-3"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.3205\/000307"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-016-0300-z"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2685"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.12.013"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2263166"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069132"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2026.2651404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:23:04Z","timestamp":1776068584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2026.2651404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/20523211.2026.2651404"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2026.2651404","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2651404"}}